UBS Maintains a 'Neutral' on GenOn Energy (GEN); Running the Retirement Math
Get Alerts GEN Hot Sheet
Price: $27.48 -3.51%
Rating Summary:
8 Buy, 8 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 21 | New: 20
Rating Summary:
8 Buy, 8 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 21 | New: 20
Join SI Premium – FREE
UBS maintains a 'Neutral' on GenOn Energy (NYSE: GEN) price target lowered from $3.25 to $3.00.
UBS analyst says, "We are modestly lowering our EBITDA estimates to reflect 3QA results, mgmt’s CSAPR guidance, as well as the latest commodities. We note generation guidance was revised down more than we expected (-10 TWh vs. 2Q11 for ‘12), reiterating our belief that ‘15+ EBITDA is in a range of ~$600 Mn post-retirements."
UBS cuts FY11 EPS estimate from (0.07) to (0.11) and FY12 from (0.29) to (0.45).
For an analyst ratings summary and ratings history on GenOn Energy click here. For more ratings news on GenOn Energy click here.
Shares of GenOn Energy closed at $2.78 yesterday.
UBS analyst says, "We are modestly lowering our EBITDA estimates to reflect 3QA results, mgmt’s CSAPR guidance, as well as the latest commodities. We note generation guidance was revised down more than we expected (-10 TWh vs. 2Q11 for ‘12), reiterating our belief that ‘15+ EBITDA is in a range of ~$600 Mn post-retirements."
UBS cuts FY11 EPS estimate from (0.07) to (0.11) and FY12 from (0.29) to (0.45).
For an analyst ratings summary and ratings history on GenOn Energy click here. For more ratings news on GenOn Energy click here.
Shares of GenOn Energy closed at $2.78 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cullinan Oncology Inc. (CGEM) PT Raised to $27 at UBS
- William Blair Downgrades Enovix Corporation (ENVX) to Market Perform
- EyePoint Inc. (EYPT) PT Lowered to $8 at Jefferies
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share